共 50 条
- [41] Interim results from the first open-label, multicenter, phase IIIb study investigating the combination of pertuzumab with subcutaneous trastuzumab and a taxane in patients with HER2-positive metastatic breast cancer (SAPPHIRE)CANCER RESEARCH, 2016, 76Woodward, N.De Boer, R. H.Redfern, A.White, M.Young, J.Truman, M.Beith, J.
- [42] Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancerCancer Chemotherapy and Pharmacology, 2017, 79 : 489 - 495Toshio ShimizuKimio YonesakaHidetoshi HayashiTsutomu IwasaKoji HarataniHironori YamadaShoichi OhwadaEmi KamiyamaKazuhiko Nakagawa
- [43] BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody- drug conjugate, in patients with locally advanced or metastatic solid tumours: afirst-in-human, open-label, multicentre, phase 1 studyLANCET ONCOLOGY, 2024, 25 (07): : 901 - 911Ma, YuxiangHuang, YanZhao, YuanyuanZhao, ShenXue, JinhuiYang, YunpengFang, WenfengGuo, YeHan, YaqianYang, KunyuLi, YongshengYang, JunFu, ZhenmingChen, GangChen, LikunZhou, NingningZhou, TingZhang, YaxiongZhou, HuaqiangLiu, QianwenZhu, YiZhu, HaiXiao, SaZhang, LiZhao, Hongyun
- [44] Phase I, first-in-human, open-label, dose-escalation study of U3-1565, a fully human anti-HB-EGF monoclonal antibody, in patients with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)Moore, Kathleen N.Bendell, Johanna C.Olszanski, Anthony J.Desai, MadhuriJansen, MendelScheyer, Richard DavidSenaldi, GiorgioLoRusso, Patricia
- [45] BL-M07D1, an antibody- drug conjugate directed to HER2 in patients with locally advanced or metastatic Breast Cancer with HER2-positive/low-expression and other solid tumors: Results from a first-in-human phase 1 studyCANCER RESEARCH, 2024, 84 (09)Song, ErweiYao, HeruiSun, MeiliZong, HongLin, RongboZou, WenDing, MuranYu, JingXiao, SaWang, HongweiZhu, HaiOlivo, MartinZhu, Yi
- [46] A multiple center, open-label, single-arm, phase II clinical trial of MRG002, an HER2-targeted antibody-drug conjugate, in patients with HER2-low expressing advanced or metastatic breast cancer.JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Jiang, ZefeiSun, TaoWang, XiaojiaLiu, QiangYan, MinTong, ZhongshengGeng, CuizhiTang, JinhaiYin, YongmeiYu, GuohuaWang, JingfenSu, WuyunWang, ShusenPan, YueyinYang, Hua
- [47] A novel anti-HER2 monoclonal antibody IAH0968 in HER2-positive, heavily pretreated solid tumors: Results from a phase Ia/Ib, first-in-human, open-label, single-center study.JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Song, NaTeng, YueeTeng, ZanShi, JingJin, BoQu, JingleiZhang, LingyunYu, PingZhao, LeiWang, JinLi, AodiTong, LinlinLiu, YunpengQu, Xiujuan
- [48] Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabineBREAST CANCER, 2018, 25 (03) : 370 - 374Pivot, XavierIm, Seock AhGuo, MatthewMarme, Frederik
- [49] Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabineBreast Cancer, 2018, 25 : 370 - 374Xavier PivotSeock Ah ImMatthew GuoFrederik Marmé
- [50] Updated safety results from the first multicenter, open-label, phase IIIb study investigating the combination of pertuzumab with subcutaneous trastuzumab and a taxane in patients with HER2-positive metastatic breast cancer (SAPPHIRE)CANCER RESEARCH, 2017, 77Woodward, N.De Boer, R. H.Redfern, A.White, M.Roberts, W.Truman, M.Beith, J.